FDA seeks more data from Teva on Treanda cancer drug Globes The US Food and Drug Administration (FDA) is asking more data from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) about its first line treatment for non-Hodgkin lymphoma, Treanda, which is administered in combination with rituximab. Teva asked for more details on Treanda for non-Hodgkin lymphoma |
